Gout Medical Services in China

Gout is a common, painful form of inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in joints and soft tissues, resulting from chronic hyperuricemia—serum uric acid levels exceeding 6.8 mg/dL. It predominantly affects the first metatarsophalangeal joint (podagra), but can involve ankles, knees, wrists, fingers, and elbows. Pathogenesis involves impaired renal urate excretion (accounting for ~90% of cases) or, less commonly, overproduction due to enzymatic defects (e.g., PRPS hyperactivity, HGPRT deficiency), dietary purine excess, or metabolic comorbidities. Urate crystal deposition triggers NLRP3 inflammasome activation, leading to IL-1β–driven neutrophil infiltration, synovial inflammation, and acute flares lasting 3–10 days untreated. Chronic gout may progress to tophaceous deposits, joint erosion, and irreversible damage if uncontrolled. Epidemiologically, gout affects approximately 1–4% of adults globally, with rising prevalence in China—estimated at 1.1–3.2% among adults aged ≥18 years—and higher incidence in men (peak onset 40–50 years) and postmenopausal women. Key modifiable risk factors include obesity (BMI ≥25 kg/m²), excessive alcohol intake (especially beer and spirits), high-purine diets (red meat, shellfish, organ meats), fructose-sweetened beverages, hypertension, chronic kidney disease (CKD stages 2–4), diuretic use (e.g., thiazides), and metabolic syndrome. Non-modifiable risks include male sex, aging, genetic predisposition (e.g., SLC2A9, ABCG2 variants), and family history. Gout significantly impairs quality of life: recurrent flares cause severe pain, functional limitation, work absenteeism, sleep disruption, anxiety, and depression. Patients often report reduced mobility, social withdrawal, and diminished participation in daily activities—even during intercritical periods. Untreated gout increases long-term cardiovascular risk (e.g., myocardial infarction, stroke) and accelerates CKD progression. Early diagnosis via clinical criteria (e.g., ACR/EULAR 2015 classification), serum uric acid testing, synovial fluid analysis (gold standard for crystal identification), and dual-energy CT (for tophus detection) is essential. Management requires a dual-phase strategy: rapid anti-inflammatory control of acute flares (NSAIDs, colchicine, or glucocorticoids), followed by long-term urate-lowering therapy (ULT) targeting serum uric acid <6.0 mg/dL (<5.0 mg/dL for tophaceous disease) using xanthine oxidase inhibitors (allopurinol, febuxostat) or uricosurics (lesinurad, benzbromarone where available). Lifestyle modification—including weight loss, low-purine diet, alcohol moderation, hydration, and avoidance of fasting or rapid weight loss—is foundational. Patient education on adherence, flare prophylaxis during ULT initiation, and comorbidity management is critical for sustainable outcomes.

Gout is a crystalline arthropathy resulting from the deposition of monosodium urate (MSU) crystals in joints, soft tissues, and kidneys, precipitated by chronic hyperuricemia—defined as serum uric acid (sUA) concentration exceeding 6.8 mg/dL, the physiological saturation threshold for uric acid at 37°C. The primary cause of gout is sustained elevation of serum uric acid, which arises from either overproduction or, more commonly, underexcretion of uric acid. Uric acid is the end-product of purine metabolism in humans; unlike most mammals, humans lack functional uricase enzyme, rendering uric acid poorly soluble and prone to crystallization when concentrations exceed solubility limits. Approximately 90% of gout cases are attributable to renal underexcretion of uric acid, mediated by dysfunction of urate transporters—including URAT1 (SLC22A12), GLUT9 (SLC2A9), ABCG2, and NPT1—leading to reduced fractional excretion of uric acid (FEUA < 5%). Overproduction accounts for ~10% of cases and may stem from enzymatic defects such as hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency (Lesch-Nyhan syndrome), phosphoribosylpyrophosphate (PRPP) synthetase overactivity, or increased cellular turnover (e.g., in hematologic malignancies or psoriasis).

Acute gout flares are triggered by rapid fluctuations in sUA—particularly sudden decreases (e.g., after initiation of urate-lowering therapy) or increases (e.g., due to dehydration or alcohol intake)—which promote crystal shedding, phagocytosis by neutrophils, and activation of the NLRP3 inflammasome, culminating in IL-1β–driven synovial inflammation. Common acute triggers include excessive dietary purine intake (e.g., red meat, shellfish, organ meats), ethanol consumption (especially beer and spirits, which both increase purine synthesis and impair renal urate excretion), diuretic use (particularly thiazides and loop diuretics), acute kidney injury, fasting or rapid weight loss, surgery, trauma, and intercurrent infection.

Established risk factors encompass demographic, metabolic, and clinical variables. Age and sex are prominent: gout incidence rises sharply after age 40 in men and postmenopausal women, reflecting hormonal influences—estrogen enhances renal urate clearance, while testosterone may modestly promote uricosuria. Obesity (BMI ≥30 kg/m²) independently increases risk via adipose tissue-driven inflammation, insulin resistance (which reduces renal urate excretion), and increased purine turnover. Metabolic syndrome—comprising hypertension, dyslipidemia, central obesity, and impaired glucose tolerance—is strongly associated with hyperuricemia and gout. Chronic kidney disease (CKD), particularly stages 3–5, impairs urate clearance and doubles gout prevalence. Cardiovascular disease, heart failure, and type 2 diabetes further elevate risk through shared pathophysiological pathways including endothelial dysfunction and oxidative stress.

Genetic factors contribute significantly to gout susceptibility, with heritability estimates ranging from 60–70%. Genome-wide association studies (GWAS) have identified over 30 loci associated with serum uric acid levels and gout risk. Key variants include loss-of-function mutations in ABCG2 (a major gut and renal urate exporter), accounting for up to 10% of early-onset gout; polymorphisms in SLC2A9 (GLUT9), which modulates renal urate reabsorption; and variants in SLC22A12 (URAT1), influencing proximal tubular urate handling. Polygenic risk scores integrating these variants improve prediction of hyperuricemia and gout onset, especially in individuals with family history.

Environmental and lifestyle determinants substantially modulate risk. Dietary patterns rich in fructose (e.g., sugar-sweetened beverages) elevate uric acid by accelerating ATP degradation and increasing purine synthesis. High-purine diets, excessive alcohol, and chronic dehydration exacerbate hyperuricemia. Occupational exposures—such as lead toxicity (causing chronic interstitial nephritis and reduced urate excretion) and occupational heat stress with recurrent dehydration—are underrecognized contributors. Socioeconomic factors, including limited access to healthcare, delayed diagnosis, and inconsistent adherence to urate-lowering therapy (ULT), perpetuate disparities in gout burden. Additionally, certain medications—including low-dose aspirin (<2 g/day), cyclosporine, pyrazinamide, and ethambutol—interfere with urate transport and may precipitate gout in predisposed individuals. Importantly, while hyperuricemia is necessary for gout development, only ~10–20% of hyperuricemic individuals progress to clinical gout over decades, underscoring the multifactorial interplay among genetic susceptibility, environmental exposures, and inflammatory priming in disease expression.

Gout is a crystalline arthropathy resulting from the deposition of monosodium urate (MSU) crystals in joints, soft tissues, and kidneys due to chronic hyperuricemia—defined as serum uric acid concentration exceeding 6.8 mg/dL (404 µmol/L), the saturation threshold for MSU in physiological conditions. As a disorder managed primarily within Endocrinology, gout reflects dysregulation in purine metabolism and/or renal urate handling, often intertwined with metabolic syndrome, insulin resistance, hypertension, chronic kidney disease, and obesity.

Early symptoms of gout are frequently subtle and nonspecific. Many patients remain asymptomatic for years despite persistent hyperuricemia—a state termed asymptomatic hyperuricemia. However, some individuals report prodromal signs preceding acute flares: mild joint stiffness or transient discomfort in the first metatarsophalangeal (MTP) joint, intermittent low-grade swelling without overt inflammation, or vague fatigue and malaise. These early manifestations may be overlooked or attributed to overuse or minor trauma. Notably, serum uric acid levels do not reliably correlate with symptom onset; approximately 10% of individuals with sustained hyperuricemia develop clinical gout over a decade, while others experience flares at near-normal or even borderline-high uric acid concentrations, particularly during rapid fluctuations (e.g., post-diuretic initiation, fasting, or alcohol binges).

Typical symptoms characterize the acute gouty arthritis flare: sudden, severe, excruciating pain—often beginning nocturnally—most commonly affecting the first MTP joint (podagra), though the midfoot, ankle, knee, wrist, and small hand joints are also frequent sites. The involved joint exhibits classic signs of acute inflammation: intense erythema (shiny, taut, violaceous skin), marked swelling, exquisite tenderness to even light touch or bedsheet pressure, and functional impairment. Fever (low-grade to moderate) and systemic leukocytosis may accompany severe flares. Attacks typically peak within 24 hours and resolve spontaneously over 7–14 days if untreated. Recurrent flares become more frequent, longer-lasting, and less localized over time—evolving from monoarticular to oligoarticular or polyarticular patterns. Tophaceous deposition—visible, firm, non-tender subcutaneous nodules composed of MSU crystals—may emerge after ~10 years of uncontrolled disease, commonly at the helix of the ear, olecranon bursa, Achilles tendon, or finger extensor surfaces. Tophi can ulcerate, discharge chalky material, and predispose to secondary infection.

Accompanying symptoms reflect comorbidities and systemic inflammation. Patients frequently report metabolic symptoms: central adiposity, dyslipidemia-related xanthomas, or exertional dyspnea suggestive of underlying cardiovascular disease. Renal involvement may manifest as asymptomatic microscopic hematuria or mild proteinuria; in advanced cases, patients describe flank pain, reduced urine output, or recurrent urinary tract infections—signs of uric acid nephrolithiasis or chronic urate nephropathy. Fatigue, low-grade fevers, and depressed mood are common during active flares, likely mediated by interleukin-1β (IL-1β) and other proinflammatory cytokines released in response to MSU crystal phagocytosis by macrophages.

Complications arise from persistent hyperuricemia and recurrent inflammation. Chronic tophaceous gout leads to irreversible joint destruction, cartilage erosion, bone erosions (‘rat-bite’ lesions on radiography), and deformity. Uric acid nephrolithiasis occurs in 10–25% of gout patients, presenting with colicky flank pain, hematuria, and obstructive uropathy; stones are radiolucent on plain X-ray but detectable via non-contrast CT or ultrasound. Chronic urate nephropathy—interstitial infiltration by urate crystals and inflammatory cells—contributes to progressive decline in glomerular filtration rate (GFR), especially when compounded by hypertension or diabetes. Cardiovascular morbidity is markedly elevated: gout independently associates with increased risk of myocardial infarction, heart failure, and ischemic stroke, partly attributable to shared inflammatory pathways and endothelial dysfunction. Additionally, chronic gout increases susceptibility to septic arthritis (due to impaired neutrophil function in hyperuricemic milieu) and osteomyelitis adjacent to eroded bone or draining tophi.

Diagnosis relies on a combination of clinical assessment, laboratory testing, and imaging. Serum uric acid measurement is essential but insufficient alone—levels must be interpreted in context (e.g., normal during acute flare due to IL-1–mediated renal uricosuria). Synovial fluid analysis remains the gold standard: identification of negatively birefringent, needle-shaped MSU crystals under compensated polarized light microscopy confirms diagnosis. Joint aspiration should be performed during active inflammation, avoiding corticosteroid injection prior to sampling. Dual-energy CT (DECT) is increasingly utilized for noninvasive detection of urate deposits, quantifying tophus burden and monitoring treatment response; it demonstrates high specificity (>90%) for urate, though sensitivity varies with crystal load and scanner calibration. Ultrasound reveals the ‘double-contour sign’ (hyperechoic band over articular cartilage), tophi, and aggregates—highly sensitive for early crystal deposition. Plain radiographs show characteristic punched-out, well-circumscribed bone erosions with overhanging edges in chronic disease but lack sensitivity in early gout.

Differential diagnosis is critical, as several conditions mimic gout clinically. Septic arthritis presents similarly with acute monoarticular inflammation but requires urgent exclusion via synovial fluid culture and PCR; coexistence of gout and infection is possible. Pseudogout (calcium pyrophosphate dihydrate [CPPD] deposition disease) causes acute flares indistinguishable from gout but features positively birefringent rhomboid crystals on microscopy and chondrocalcinosis on imaging. Rheumatoid arthritis may present with acute-onset monoarthritis early on but typically evolves into symmetric, erosive polyarthritis with positive RF/anti-CCP antibodies and synovitis on MRI. Reactive arthritis follows gastrointestinal or genitourinary infections and features dactylitis, enthesitis, and conjunctivitis. Cellulitis mimics gout’s erythema and swelling but lacks joint-specific tenderness and shows no intra-articular fluid. Hemochromatosis-associated arthropathy affects second and third MCP joints and wrists, with associated bronze skin and elevated ferritin. Finally, sarcoidosis and myeloproliferative disorders may cause hyperuricemia secondary to increased cell turnover, necessitating evaluation for underlying malignancy or granulomatous disease when uric acid elevation is disproportionate or refractory to standard management.

Gout is a chronic, inflammatory arthropathy driven by hyperuricemia—elevated serum uric acid (sUA) concentrations exceeding the physiological solubility threshold of approximately 6.8 mg/dL—leading to monosodium urate (MSU) crystal deposition in joints, soft tissues, and kidneys. As a metabolic disorder frequently intersecting with insulin resistance, hypertension, chronic kidney disease (CKD), and cardiovascular disease, gout management falls under the purview of endocrinology due to its pathophysiological links with purine metabolism, renal handling of uric acid, and comorbid metabolic syndrome. Optimal treatment requires a stratified, phase-specific approach encompassing acute attack suppression, intercritical management, and long-term urate-lowering therapy (ULT) to prevent structural joint damage, tophi formation, and renal impairment.

Conservative treatment forms the cornerstone of gout care and must be initiated at diagnosis. Lifestyle modification is evidence-based and non-pharmacologic: patients are advised to limit high-purine foods (e.g., organ meats, shellfish, yeast extracts), avoid sugar-sweetened beverages and excessive alcohol—particularly beer and spirits—and maintain a healthy body weight through gradual, sustainable weight loss (≥5% body weight reduction improves sUA by ~0.5–1.0 mg/dL). Hydration should exceed 2 L/day to promote uric acid excretion and reduce nephrolithiasis risk. Patients with CKD or heart failure require individualized fluid targets. Dietary patterns such as the DASH (Dietary Approaches to Stop Hypertension) diet and Mediterranean diet demonstrate modest but clinically meaningful reductions in sUA and gout flares. Importantly, fasting and rapid weight loss are contraindicated, as they induce ketosis and transient hyperuricemia. Joint protection strategies—including temporary activity modification during flares and ergonomic assessment for occupational stressors—are integrated into comprehensive conservative care.

Pharmacotherapy is guided by disease phase and patient-specific factors including renal function, comorbidities, and flare frequency. For acute gout attacks, first-line agents include nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin or naproxen (if no contraindications), low-dose colchicine (1.2 mg followed by 0.6 mg one hour later, then 0.6 mg once or twice daily), or intra-articular or systemic glucocorticoids (e.g., oral prednisone 30–35 mg/day tapered over 7–10 days). IL-1 inhibitors (e.g., anakinra) are reserved for refractory cases or contraindications to conventional agents. Inter-critical management focuses on ULT initiation only after resolution of acute inflammation—typically ≥2 weeks post-flare—to avoid flare precipitation. First-line ULT is allopurinol, titrated gradually (starting at 100 mg/day in CKD stage 3+; 200–300 mg/day otherwise) to achieve and maintain sUA <5.0 mg/dL (target <4.0 mg/dL in patients with tophi or frequent flares). Febuxostat is an alternative xanthine oxidase inhibitor for allopurinol-intolerant or non-responsive patients, though cardiovascular safety requires careful evaluation. Uricosurics (e.g., probenecid, benzbromarone—available in China but not FDA-approved) enhance renal uric acid excretion and are preferred in underexcretors (fractional excretion of uric acid >5–10%) with preserved renal function. Lesinurad is used adjunctively with xanthine oxidase inhibitors in refractory cases. All ULT regimens mandate concomitant anti-inflammatory prophylaxis (colchicine 0.5–0.6 mg once or twice daily for ≥6 months) to mitigate flare risk during urate-lowering.

Surgical intervention is rarely indicated but plays a defined role in advanced gout. Tophaceous gout with large, ulcerating, infected, or mechanically disabling tophi may necessitate surgical debridement or excision—particularly when tophi compress nerves (e.g., carpal tunnel), erode bone, or impair joint mobility. Arthroscopic or open synovectomy may be performed for chronic destructive gouty arthritis unresponsive to medical therapy. Joint replacement (e.g., total knee or hip arthroplasty) is considered in end-stage gout with severe cartilage destruction and functional limitation. Surgery is always preceded by optimal ULT to minimize recurrence and perioperative flare risk; sUA should be <5.0 mg/dL for ≥6 months preoperatively. Postoperative ULT adherence remains critical, as surgical removal of tophi does not eliminate systemic urate burden.

Treatment advantages in China reflect robust integration of traditional and modern medicine, advanced diagnostic infrastructure, and national clinical guidelines aligned with international standards (e.g., EULAR and ACR). Chinese endocrinology centers widely employ dual-energy CT (DECT) for precise, non-invasive MSU crystal detection—even in asymptomatic hyperuricemia—facilitating early intervention. Pharmacovigilance systems monitor allopurinol hypersensitivity syndrome (AHS), and HLA-B*58:01 genotyping is increasingly available prior to allopurinol initiation, significantly reducing AHS incidence. Benzbromarone, unavailable in many Western countries, offers a potent uricosuric option for Chinese patients with normal renal function and hepatic monitoring. Moreover, standardized integrative protocols incorporating evidence-based Chinese herbal formulas (e.g., Tongfengling decoction, shown in RCTs to reduce sUA and flare frequency when combined with allopurinol) are offered in tertiary hospitals under strict pharmacognosy quality control. National health insurance coverage for ULT and biologics has improved access, while telemedicine platforms enable longitudinal sUA monitoring and medication titration in rural populations.

Recovery and long-term management emphasize patient education and structured follow-up. Patients should understand that gout is controllable but not curable without lifelong adherence to ULT. sUA levels must be monitored every 2–4 weeks during dose titration and quarterly thereafter once target is achieved. Annual assessment includes renal function (eGFR, urinalysis), liver enzymes, 24-hour urinary uric acid (to guide uricosuric use), and musculoskeletal ultrasound or DECT if tophus burden is uncertain. Flare diaries and digital symptom trackers improve self-management. Psychosocial support addresses stigma and treatment fatigue; multidisciplinary teams—including endocrinologists, rheumatologists, dietitians, and pharmacists—optimize outcomes. Ultimately, successful gout management hinges on sustained sUA control, proactive flare prevention, and holistic attention to metabolic health—transforming gout from a recurrent, debilitating condition into a well-regulated chronic disease.